CpdA's selective GR actions and to a lesser extent its antagonistic AR actions also contribute to the compound's ability to inhibit bladder cancer cell proliferation, colony formation, cell migration and invasion, and to increase cell cycle arrest and apoptosis [41]. The gene discussed is NR3C1; the disease is urinary bladder cancer.